Great to see they are moving right along. I also like that management does not want to back down from the FDA.
"Now with ARYMO ER stocked at key wholesale distribution locations and having begun discussions with payers, our salesforce is well positioned to begin educating healthcare providers about the risks and benefits of ARYMO ER," said Bob Radie, president and chief executive officer of Egalet. "ARYMO ER strengthens our portfolio of pain products which includes SPRIX® Nasal Spray and OXAYDO®."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.